FOSUN HEALTH Logo

Prostate Cancer Causes

catalogue

Prostate Cancer Causes

Prostate Cancer Causes

Prostate cancer has no single cause, and the largest single factor is simply getting older: the disease is uncommon before 50 and its incidence rises steeply after that. On top of age, inherited DNA repair faults and family history explain a meaningful share of risk, and a small number of exposures are associated with more aggressive disease rather than with developing it at all.

Age: the strongest factor

Prostate cancer is a disease of ageing, and this is not a statistical accident but a reflection of how it arises. The prostate continues to grow throughout life under the influence of testosterone and related hormones, and the glandular cells divide repeatedly over decades. Each division carries a small chance of a mutation that is not repaired, and over eighty years of divisions those chances accumulate. The tissue is simply exposed to more opportunities for error than almost any other organ.

The practical pattern is well defined: the disease is uncommon before 50, becomes increasingly common in men in their sixties and seventies, and autopsy studies have long found small, clinically silent tumours in a substantial proportion of older men who died of other causes. That last observation is the reason the detection debate exists at all — much of what is found in older men would never have caused symptoms.

The honest implication is twofold. Age cannot be modified, so it functions as a trigger to discuss testing rather than something to act against. And because many tumours found at older ages are indolent, the appropriate response to a diagnosis is a risk assessment rather than an automatic decision to treat — which is precisely what grading and active surveillance are for.

Family history and BRCA2

Inherited risk is the part of this disease's causal picture where the practical pay-off is largest, because it changes screening and family advice rather than merely explaining a statistic. Three patterns matter:

  • A father or brother with prostate cancer — this roughly doubles a man's risk, and the earlier the relative was diagnosed, the more it matters. Two or more affected relatives raise it further.
  • BRCA2 variants — the gene best known for breast and ovarian cancer carries a substantially increased prostate cancer risk in men, and the tumours that develop are more likely to be higher grade and to present at a younger age. BRCA2 testing is also what unlocks PARP-inhibitor treatment in advanced disease.
  • Lynch syndrome — the hereditary mismatch repair condition raises prostate cancer risk alongside the better-known risks of colon and endometrial cancer, and it is worth knowing about because the tumours can behave more aggressively.

Testing is offered according to family history and stage rather than universally: the key triggers are a close relative diagnosed young, several affected relatives, known BRCA2 or Lynch syndrome in the family, or advanced disease where the result would change treatment. When a germline variant is found, the implication extends beyond the patient — siblings and children can be tested, and those who carry it gain a defined surveillance plan rather than a vague sense of risk.

Ancestry and hormones

Men of African ancestry have both a higher incidence of prostate cancer and a tendency for it to appear earlier and to behave more aggressively. The excess risk is not explained by socioeconomic factors alone; it is partly genetic and partly about how the disease is detected and treated, and it is the reason screening discussions and earlier testing thresholds differ for this group. Men of Asian ancestry, by contrast, have had a lower incidence historically — though the incidence is rising as diets and lifespans change.

The hormonal element runs through the whole disease rather than sitting alongside it. Testosterone and its conversion product dihydrotestosterone drive the growth of both normal prostate tissue and prostate cancer cells, which is why benign hyperplasia is universal in ageing men and why suppressing testosterone is the most effective systemic treatment for the cancer. There is no evidence that having a naturally high testosterone level causes the disease, and the hypothesis that higher levels increase risk has not been supported by the data — what is established is that the tumours depend on the hormone once they exist.

Smoking, weight and activity

The lifestyle factors here behave differently from those in many other cancers: they are associated less with whether a man develops prostate cancer and more with how aggressive the disease turns out to be. Smoking is the clearest example — it is linked to a higher risk of dying from prostate cancer and to more aggressive disease, rather than to a dramatic rise in incidence. Obesity behaves similarly: it is associated with more aggressive tumours and with a higher risk of recurrence after treatment.

A sedentary life, a diet very high in processed meat and low in vegetables, and vitamin D deficiency have all been studied, with weaker though plausible associations. What can be said with confidence is limited: no dietary change has been shown to prevent prostate cancer, and supplements — including selenium and vitamin E — have failed to show benefit in large trials, with one trial suggesting harm. Exercise retains an independent and well-evidenced role for a different reason: it mitigates the muscle loss, bone loss and cardiovascular risk that hormone therapy causes.

The realistic framing is therefore not prevention but risk modification, and it applies most to men who already have a diagnosis: maintaining muscle and cardiovascular fitness measurably improves how treatment is tolerated, and avoiding weight gain and smoking reduces the probability of aggressive disease.

What does not cause it

A number of widely held beliefs are not supported by the evidence, and correcting them matters because they cause unnecessary anxiety or false reassurance:

  • Vasectomy — early reports suggested a link; the better-designed studies that followed have not confirmed an increase in risk, and major guidelines no longer treat it as a risk factor.
  • Sexual activity and sexually transmitted infections — a common worry, but no infection is established as a cause of prostate cancer in the way HPV causes cervical cancer.
  • Benign prostatic enlargement — the two conditions commonly coexist, but benign hyperplasia does not transform into cancer; they arise in different zones of the gland.
  • A naturally high testosterone level, or testosterone therapy — the evidence does not support testosterone therapy causing prostate cancer, though it is used cautiously in men with a history of the disease.
  • Cycling or a sedentary occupation — cycling causes perineal pressure and can raise PSA temporarily, but it is not a cause of the cancer.

The reason to be precise about this list is that false causes create false reassurance in the opposite direction: a man who believes the disease is caused by something he has avoided may conclude he does not need to think about testing at all. Age, family history and genes are the factors that actually shape that decision.

Who is at higher risk

Bringing the sections together, the profile in plain terms — the disease is uncommon before 50, and risk rises with:

  • Increasing age, particularly beyond 60
  • A father, brother or son with prostate cancer, especially if diagnosed young
  • A known BRCA2 variant, Lynch syndrome, or a strong family history of breast, ovarian or pancreatic cancer
  • African ancestry, where onset tends to be earlier and the disease more aggressive
  • Smoking and obesity, which are associated with more aggressive rather than more frequent disease

Two groups deserve an arrangement rather than a symptom-triggered response. Men with a known BRCA2 variant or Lynch syndrome should have a surveillance plan defined with a genetics-informed team, and their relatives should be offered testing. And men with several affected relatives should discuss the age at which to begin PSA testing, because the usual starting point is not necessarily the right one when risk is concentrated — the prevention page sets out how those discussions work.

Frequently Asked Questions

Is prostate cancer hereditary?

Partly. Most cases occur without any family pattern, but a father or brother with the disease roughly doubles a man's risk, and a small proportion of cases are driven by inherited faults in DNA repair genes — above all BRCA2, and also Lynch syndrome. That inherited share matters disproportionately because it changes what can be done: carriers can be tested, monitored from a younger age, and in advanced disease may have access to PARP-inhibitor treatment. A close relative diagnosed young, or several affected relatives, is the trigger to ask about testing.

Does a high sex drive or testosterone level cause prostate cancer?

No — the evidence does not support it. Prostate cancer cells depend on testosterone once they exist, which is why suppressing the hormone is the most effective systemic treatment, but studies have not shown that naturally higher testosterone levels cause the disease, and testosterone therapy has not been shown to cause it either. This is a common source of unnecessary worry, and correcting it matters because it can push men toward either false alarm or false reassurance.

Should my sons or brothers be tested if I have prostate cancer?

It is worth asking, and the answer depends on your age at diagnosis and whether a germline variant is found. If you carry a BRCA2 or Lynch syndrome diagnosis, relatives can be offered genetic testing, and carriers gain a defined surveillance plan. Even without a known variant, a first-degree relative with prostate cancer is at roughly double the usual risk, so the reasonable step is a conversation about when to begin PSA testing rather than a decision to test everyone immediately.

Can I reduce my risk by changing my diet?

No dietary change has been shown to prevent prostate cancer, and the large trials of selenium and vitamin E failed to show benefit — one suggested harm. What diet and exercise do affect is the aggressiveness of disease and how treatment is tolerated: obesity and smoking are associated with more aggressive tumours, while exercise protects muscle and bone during hormone therapy and improves cardiovascular health. The honest summary is that lifestyle modification is worth doing for those reasons, not as a way to avoid the disease.

Patient Stories

Stories from our prostate cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Know where you stand on inherited risk

A family history of prostate, breast or pancreatic cancer may justify genetic testing. Send what you know of the family tree and any previous results, and our team will tell you whether testing and earlier surveillance are worth arranging — in writing within 48 hours.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*